Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl Sells 3,084 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl sold 3,084 shares of the firm’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $154,539.24. Following the sale, the general counsel now owns 51,712 shares of the company’s stock, valued at $2,591,288.32. This represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Bryan Wahl also recently made the following trade(s):

• On Tuesday, March 18th, Bryan Wahl sold 3,341 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $46.29, for a total value of $154,654.89.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS opened at $49.97 on Friday. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The firm’s 50-day moving average price is $48.48 and its two-hundred day moving average price is $45.35. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28. The stock has a market capitalization of $1.92 billion, a P/E ratio of -13.12 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The firm had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million. As a group, sell-side analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several large investors have recently made changes to their positions in TARS. Mutual of America Capital Management LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the third quarter valued at approximately $4,291,000. Jennison Associates LLC increased its stake in shares of Tarsus Pharmaceuticals by 47.2% in the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after purchasing an additional 698,712 shares during the period. Intech Investment Management LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the third quarter valued at approximately $282,000. Charles Schwab Investment Management Inc. increased its stake in shares of Tarsus Pharmaceuticals by 10.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 290,009 shares of the company’s stock valued at $9,538,000 after purchasing an additional 28,130 shares during the period. Finally, FMR LLC increased its stake in shares of Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after purchasing an additional 3,537 shares during the period. Institutional investors and hedge funds own 90.01% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on TARS. HC Wainwright reaffirmed a “buy” rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Jefferies Financial Group increased their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Oppenheimer increased their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Guggenheim reaffirmed a “buy” rating and set a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Finally, Barclays reduced their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $63.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.